Rapport Therapeutics Inc.
Rapport Therapeutics Inc.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Seizures, Focal, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 3 | 2026-10-08 | NCT07563881 | |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Seizures, Focal, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 3 | 2026-09-02 | NCT07594119 | |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, bipolar I disorder, nervous system disorder | Active, not recruiting | Phase 2 | 2026-08-10 | NCT07046494 | |
| A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Seizures, Focal, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 2 | 2026-01-23 | NCT07219407 |